Latest Conference Articles

Physicians should remain vigilant in counseling their patients away from activities that pose a high risk of head injuries.

Our understanding of autism has improved significantly over the past decade. Among several discoveries, we now know that children with autism interpret faces differently than their peers without the condition.

In response to patient concerns about dosing options and duration of effect, researchers at Shire Pharmaceuticals created Mydayis for the treatment of ADHD symptoms.

Over the last decade, physicians have gained significant ground in their understanding of autism. Here's what we know now.

Psychedelics like psilocybin have been receiving attention from psychiatrists on and off for decades. Here's what we've learned, and what's on the horizon.

When asked about an ideal medication, most survey respondents said such a drug would last all day.

The ROPA-DOP trial showed that low-dose dopamine had an insignificant impact on patient renal function, nor a significant trend toward greater diuresis.

Scott Solomon, MD, and Alvin Chandra, MD, discuss the findings of the PARADIGM-HF and QoL trial, and sacubitril's effect on HF patients quality of life.

Michael Felker, MD, talks about the results of the GUIDE-IT trial and the use of natriuretic peptide-guided therapy for patients with HFrEF.

Parental rejection, abandonment, physical and sexual abuse double the victim's rates of depression, inflammation, metabolic disorders and chronic medical illnesses.

Patients struggling with addiction can be difficult to treat. Following best practices can help simplify a complex process.

Patients ask about side effects a lot, but physicians aren't always keen to listen, according to Michael Thase, MD. Here's why they should.

Ketamine shows huge promise in patients with depression. Here's why it may become the next big breakthrough treatment option in depressed patients.

Lisa Rathman, MSN, of Lancaster General Hospital, discusses the benefits of subcutaneous furosemide in nursing homes and facilities outside the hospital.

Gregg Fonarow, MD; David Aguilar, MD; Rob Mentz, MD; and James Januzzi, MD, discuss the unexpected and exciting use of SGLT-2 inhibitors to treat heart failure.

Rob Mentz, MD, of Duke University Medical School, discusses the CANVAS trial and the pursuit of using SGLT-2 inhibitors to treat heart failure.

The drug showed improved symptoms across multiple doses in a 6-month study.

Gregg Fonarow, MD, of UCLA, discusses the vital importance of preventing HF in ways outside of just the available treatment options.

Mandeep Mehra, MD, President of the HFSA, discusses one of the HFSA annual meeting's themes: the prophylaxis of heart failure through behavioral and dietary adjustments.

Rob Mentz, MD; David Aguilar, MD; Mandeep Mehra, MD; and Lisa Rathman, MSN, discussed the use of team-based care in heart failure, a condition plagued by comorbidities and often treated by multiple specialists.

David Aguilar, MD, of Baylor College of Medicine, discusses the new responsibilities faced by cardiologists with the emerging onset of dual-indication medicines.

Gregg Fonarow, MD, of UCLA, spoke about the benefits of short-term treatment for keeping HF patients out of hospital, and using hospitalization as a time to learn.

Doctors should be asking questions about their patients eating habits and gastrointestinal health when screening for mental illnesses, according to Dr Raison.

There are 3 key conditions that are likely to respond well to treatment with cannabis, with many more likely to be uncovered as research increases.

Kevin Hill, MD, explains how changing cannabis policies will open new doors for clinicians.

Our understanding of the connection between the mind and microbiota has come a long way, but it still has a long way to go, according to Charles L Raison, MD.

Mandeep Mehra, MD, President of the HFSA, discusses the importance of team-based care between physicians, pharmacists, and nurse practitioners in treating heart failure.

Michael Thase, MD, explains the decision making process behind choosing drugs or therapy for patients with different types of depression.

Doris Greenberg, MD, discusses the fine line between Asperger's Syndrome and Autism Spectrum Disorder.

Bertram Pitt, MD, of the University of Michigan School of Medicine, discusses the benefits of subcutaneous furosemide keeping patients from "bouncing back" into the hospital.